Background. Isavuconazole (ISA) is a novel, water-soluble, broad-spectrum triazole antifungal available in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial (NCT00412893) assessed the efficacy and safety of ISA vs. voriconazole (VRC) in patients with invasive mold disease (IMD). Here we report on a pre-specified subset of patients from this trial who had proven/probable invasive aspergillosis (IA) (EORTC/MSG criteria) and received ≥1 dose of the study drug.
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Methods. Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. The primary efficacy endpoint was all-cause mortality (ACM) through Day 42. Overall success at end of treatment (EOT) and safety were also assessed. All diagnoses and outcomes were assessed by an independent, blinded, datareview committee. Safety data are presented as reported by the Investigator.
Results. Overall 231 patients were included in this analysis (ISA n = 123; VRC n = 108). Patient characteristics, efficacy, and safety outcomes are shown in the table. Differences in drug-related AEs between ISA and VRC were statistically significant (p < 0.001). Conclusion. In patients with documented IA, ISA had comparable efficacy to VRC, but was better tolerated than the latter. 
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